Mirtaz 30 Mg (Mirtazapine)

Product Overview

Mirtaz 30 Mg is a prescription antidepressant produced by Sun Pharmaceutical Industries Ltd. Each strip contains ten immediate‑release tablets that deliver a 30 mg dose of Mirtazapine, a tetracyclic compound classified as a noradrenergic and specific serotonergic antidepressant, or NaSSA. The medication is indicated for the treatment of major depressive disorder (MDD) and is frequently chosen when patients also experience insomnia, agitation, or loss of appetite associated with depression. Available pack sizes include 60, 90, and 120 tablets, each organized in strips of ten tablets for convenient daily use. The product is manufactured in facilities that comply with WHO‑good manufacturing practice standards, ensuring consistency and quality across batches. The tablets are film‑coated to protect the active ingredient and ensure optimal absorption. Packaging is designed to protect from moisture and light.

What is Mirtaz 30 Mg (Mirtazapine)

Mirtazapine belongs to the NaSSA class and exerts its therapeutic effect by blocking presynaptic α2‑adrenergic autoreceptors and antagonizing central histamine (H1) and serotonin (5‑HT2) receptors. This dual mechanism increases the extracellular concentrations of norepinephrine and serotonin in the brain, leading to improvements in mood, reduction of anxiety, and enhancement of sleep quality. The drug is marketed under the generic name Mirtazapine and is supplied by Sun Pharmaceutical, a company with a longstanding reputation for producing affordable, high‑quality generic medicines. Clinical studies have demonstrated that Mirtazapine is effective in a broad spectrum of depressive patients, including those with co‑occurring anxiety or sleep disturbances. The chemical formula is C19H21N5O2 and the molecular weight is 315.4 g/mol. Its long half‑life supports once‑daily dosing.

Uses and Benefits

The primary clinical use of Mirtaz 30 Mg is the treatment of major depressive disorder in adults. Physicians often select this agent when a patient’s depressive symptoms include insomnia, psychomotor agitation, or significant weight loss, because the medication’s sedating properties can address these concerns simultaneously. Compared with some other antidepressants, Mirtazapine is associated with a lower incidence of sexual dysfunction and may cause modest weight gain, which can be beneficial for underweight individuals. Additionally, the drug’s once‑daily dosing schedule simplifies adherence, and its flexible dosing allows clinicians to titrate the dose based on patient response and tolerability. Patients often notice improvements in energy levels and concentration within the first few weeks. The medication is generally well tolerated in patients with comorbid chronic illnesses.

How It Works

Pharmacologically, Mirtazapine functions as a potent antagonist at central histamine (H1) and α2‑adrenergic receptors, and as a weaker antagonist at serotonin (5‑HT2) and norepinephrine (α1) receptors. By blocking these receptors, the drug disinhibits the release of norepinephrine and serotonin, raising their levels in the synaptic cleft. This neurochemical shift contributes to mood elevation, reduced anxiety, and improved sleep architecture. The sedative effect is largely mediated through H1 receptor antagonism, which explains why many patients report feeling more rested after taking the medication in the evening. Because of its antagonism at H1 receptors, the drug produces sedation that can improve sleep onset latency. The noradrenergic effect contributes to increased alertness during daytime.

Dosage Guidelines

Mirtaz 30 Mg is generally prescribed as one tablet taken once daily, preferably in the evening due to its sedative properties. The standard starting dose for most adults is 30 mg once daily; however, some clinicians may initiate therapy at 15 mg to minimize initial drowsiness, especially in elderly patients or those with hepatic impairment. The dose should be individualized based on clinical response, tolerability, and any concomitant medications. If a dose is missed, it should be taken as soon as remembered unless it is near the time of the next dose, in which case the missed dose should be skipped. Patients with hepatic impairment may require a reduced dose. Always follow the dosing instructions provided by your prescribing clinician or on the medication label.

Side Effects

Like all pharmaceutical agents, Mirtaz 30 Mg can produce adverse effects. The most frequently reported side effects include drowsiness, dry mouth, increased appetite, and weight gain. Less common but clinically important events may involve orthostatic hypotension, dizziness, constipation, and rare occurrences of agranulocytosis or severe skin reactions. Patients should be instructed to report any new or worsening symptoms, particularly signs of allergic reaction (rash, itching, swelling) or emergent mood changes such as suicidal thoughts. Weight gain typically averages 2–5 kg over several months. Dry mouth can be managed with good oral hygiene and hydration. Regular follow‑up with a healthcare provider enables early identification and management of these risks.

Warnings and Precautions

Prior to initiating therapy with Mirtaz 30 Mg, a comprehensive medical evaluation should be performed to assess cardiac history, liver function, and any coexisting psychiatric conditions. The medication is contraindicated in individuals with known hypersensitivity to Mirtazapine or any excipients in the formulation. Caution is advised when prescribing to patients with a history of bipolar disorder, as antidepressant therapy can precipitate manic episodes. Elderly patients may be more susceptible to sedation and falls, necessitating careful dose titration. Concomitant use of monoamine oxidase inhibitors (MAOIs) must be avoided for at least 14 days before or after treatment. Pregnant or breastfeeding women should discuss the potential risks and benefits with their physician before using the medication. Patients should avoid abrupt changes in dose and should discuss any medication changes with their prescriber. The drug is not recommended for use in children under 18 years without pediatric approval.

Frequently Asked Questions

• What condition does Mirtaz 30 Mg treat? It is indicated for major depressive disorder in adults.
• How quickly does Mirtazapine relieve depressive symptoms? Clinical improvement is often observed after two to four weeks, with full effect typically seen within six to eight weeks.
• Can Mirtazapine be taken with other antidepressants? Combining antidepressants is generally not recommended without medical supervision due to the risk of serotonin syndrome.
• Is weight gain a common side effect? Yes, increased appetite and weight gain are reported in a notable proportion of patients.
• Can I consume alcohol while on Mirtazapine? Alcohol can enhance sedative effects; it is advisable to limit or avoid alcohol consumption during treatment.

For additional scientific resources, please refer to the NIH, FDA, and MedlinePlus pages on Mirtazapine. Always consult a qualified healthcare professional before making any changes to your medication regimen.

Related Products

• Vortidif 20 Mg (Vortioxetine)
• Vortidif 5 Mg (Vortioxetine)
• Pramipex 0.25 mg (Pramipexole)
• Lurasidone 40 mg (Generic)
• Ropinirole 1 mg (Generic)
• Adesam 200 mg (Ademetionine/S-Adenosyl Methionine)
• Suminat 25 mg (Sumatriptan)
• Syncapone 100 mg (Levodopa/Carbidopa/Entacapone)
• Cyclomune Eye Drop (Cyclosporin)
• Glypride 4 mg (Glimepiride)
• Natrise 15 mg (Tolvaptan)
• Simvastatin 5 mg (Simvastatin)